Navigation Links
Assessing the value of treatments to increase height
Date:3/31/2011

CLEVELAND -- Dr. Leona Cuttler, a pediatric endocrinologist and growth hormone expert from University Hospitals Rainbow Babies and Children's Hospital, is the co-author of an editorial in the New England Journal of Medicine commenting on a new study that found giving girls with Turner syndrome low doses of estrogen, as well as growth hormone, years before the onset of puberty, increases their height and offers other benefits.

With her co-author Dr. Robert L. Rosenfield, a pediatric endocrinologist with the University of Chicago Medical Center, Dr. Cuttler writes, "The use of growth hormone and estrogen has a long and often controversial history in the manipulation of growth."

About the new study, they write that the results confirm those of previous, less rigorous studies showing that treatment with growth hormone significantly increased adult height in patients with Turner's syndrome.

Drs. Cuttler and Rosenfield say the results suggest a modest but intriguing synergism between growth hormone and low-dose estrogen in promoting growth.

"The impact of these findings on practice and policy will depend not only on their statistical significance but also on whether the observed changes in height translate into clinically meaningful benefit. The ability to increase height should not be the sole yardstick for assessing benefit," the editorial states.

"Since growth hormone is well entrenched in the management of Turner's syndrome, the current findings support this aspect of practice but are not likely to change it. Yet the results underscore the need for a measured approach, which includes avoiding unrealistic expectations, when families embark on growth hormone therapy. The early use of low-dose estrogen in conjunction with growth hormone is an interesting possibility. An optimal estrogen-replacement regimen could potentially shorten the period of growth hormone treatment, reduce costs, and improve patient satisfaction. However, implementation would be hampered by the lack of a convenient means to deliver the very small estrogen doses that seem to be optimal for height augmentation."

The authors advise caution when considering supplementing growth hormone treatment with early, low-dose estrogen in Turner's syndrome. "The current results show trends that do not consistently reach significance and show only modest synergy between growth hormone and estrogen in achieving height augmentation, as compared with growth hormone alone. The suggested potential benefits of estrogen on cognition are based on earlier short-term data, and long-term data are needed. We must be concerned about unexpected risks posed by estrogen, being mindful of surprising adverse outcomes of estrogen use in other settings," they write.

According to the National Institutes of Health, Turner syndrome occurs in 1 out of 2,500 female births worldwide and develops when a female (X) sex chromosome is missing in cells or is abnormal. These girls are typically of short stature and have a loss of ovarian function.


'/>"/>

Contact: George Stamatis
george.stamatis@UHhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Mortality rates are an unreliable metric for assessing hospital quality, study finds
2. Assessing positive outcomes of phase III trials
3. Researchers validate a new test for assessing childrens and teenagers fitness to prevent morbidity
4. Assessing the science behind health claims
5. An appeal to the caregiving values of rural women for breast cancer prevention
6. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
7. Study: Consumers value safer food more than current analyses suggest
8. Supporters and opponents of a special blessing for homosexuals share many values
9. Does Club Drug Ecstasy Have Therapeutic Value?
10. Brief clarifies Social Securitys value for women
11. Biological diversity of ovarian cancer lessens value of screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Los Angeles, CA (PRWEB) , ... April 29, 2016 , ... ... Sarah Mirmelli, a mother and divorcee, shares her enthusiasm for Botox and lip injections, ... of the world famous youth oriented Coachella Valley Music and Arts Festival. The article ...
(Date:4/29/2016)... Calif. (PRWEB) , ... April 29, 2016 , ... Our ... An effective way to confront and deal with these stressors is to adopt a ... to be good for you. Risa Groux, a certified Holistic Nutritionist and the creator ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Association (CCA), is pleased to announce the launch of the GFCP Scoop ... recipes, and more. The purpose of the GFCP Scoop site is ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology: